Marker miRNA 371 in newly diagnosed testicular germ cell tumor
Studies miRNA 371 in people newly diagnosed with testicular germ cell tumor.
Key facts
- Who runs it
- Fondazione del Piemonte per l'Oncologia
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 1 Jul 2021
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 2 groups
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older with a newly diagnosed germ cell tumor. It studies whether the blood marker miRNA 371 shows if active tumor is present.
- Age
- 18 years or older
- Sex
- Male
- Disease stage
- New germ cell tumor, confirmed by tissue test or by raised HCG/AFP blood levels. Any site, stage or subtype can join, including a later second germ cell tumor. Only low or moderate risk of the disease coming back.
- Earlier treatment
- Men with Clinical Stage I testicular cancer who have surgery planned must have had the testicle removed (orchiectomy) within 42 days before registration.
- Biomarker or test result
- Blood tests for beta-HCG, AFP and LDH within 42 days before registration.
Main reasons for not taking part
- High risk of the disease coming back
- Cancer that has spread (metastatic disease)
- Tumor checks done outside the time frame set by the protocol
- Not able to follow the study schedule
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients must be ≥ 18 years of age
- Patients must have a new diagnosis of a germ cell tumor confirmed pathologically or serologically (diagnostic elevation of HCG/AFP). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible
- If surgery is planned, male patients with Clinical Stage I testicular cancer must have orchiectomy completed within 42 days prior to registration
- Patients must have risk of relapse assessment determined by the local investigator prior to registration
- Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected
- Patients must have beta-human chorionic gonadotropin (beta-HCG), alpha- fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration
- Patients must agree to provide informed consent and required blood specimens for the duration of the study
Who cannot take part
- Patients with high risk of relapse or metastatic disease
- Patients with tumour assessments beyond the time frame required by the protocol
- Patients not complaint with the protocol schedule
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a observational study aimed at evaluating miRNA 371a-3p (miRNA 371) as a specific marker for presence or absence of clinically detectable viable germ cell malignancy.
The 2 groups in the trial
- Low risk of relapse
Low risk of relapse (5-25% chance of recurrence with active germ cell malignancy): patients with low risk designation will be assigned to a low intensity schedule of biospecimen collection and imaging requirements.
- Moderate risk of relapse
Moderate risk of relapse (26-50% chance of recurrence): patients with moderate risk designation will be assigned to a higher intensity schedule of biospecimen collection and imaging requirements including early repeat imaging and classic marker determination.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Observational Cohort Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumor
- Plain-language title
- Marker miRNA 371 in newly diagnosed testicular germ cell tumorGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 5 March 2026